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https://doi.org/10.1016/j.celrep.2021.109936SUMMARYDepression symptoms are often found in patients suffering from chronic pain, a phenomenon that is yet to be
understoodmechanistically. Here, we systematically investigate the cellular mechanisms and circuits under-
lying the chronic-pain-induced depression behavior. We show that the development of chronic pain is
accompanied by depressive-like behaviors in a mouse model of trigeminal neuralgia. In parallel, we observe
increased activity of the dopaminergic (DA) neuron in the midbrain ventral tegmental area (VTA), and inhibi-
tion of this elevated VTA DA neuron activity reverses the behavioral manifestations of depression. Further
studies establish a pathway of glutamatergic projections from the spinal trigeminal subnucleus caudalis
(Sp5C) to the lateral parabrachial nucleus (LPBN) and then to the VTA. These glutamatergic projections
form a direct circuit that controls the development of the depression-like behavior under the state of the
chronic neuropathic pain.INTRODUCTION
The coexistence of pain and depression is a phenomenon well
recognized clinically (Gallagher and Verma, 1999; Bair et al.,
2003; Simon et al., 1999; Arnow et al., 2006). Symptoms of
pain and depression respond to similar drug treatments, exacer-
bate each other, and share biological pathways and neurotrans-
mitters (Blier and Abbott, 2001; Cohen et al., 2012), which may
often complicate clinical diagnosis and treatment (Gallagher
and Verma, 1999; Bair et al., 2003; Simon et al., 1999). Thus, a
key to effective treatments of comorbid pain and depression
lies in the understanding of the neurological, structural, and func-
tional basis of this comorbidity. However, our understanding of
how these distinct neurological phenomena are related on a neu-
ral circuit level is only beginning to emerge (Zhou et al., 2019).
Dopaminergic (DA) neurons in the midbrain ventral tegmental
area (VTA) were identified to encode reward prediction error (Co-
hen et al., 2012). Recent studies indicate that DA neurons in the
reward circuit of the VTA play a crucial role in the development of
depression and represent a major target of antidepressant drugs
(Lammel et al., 2014; Friedman et al., 2008; Krishnan et al., 2007;
Yadid and Friedman, 2008; Chaudhury et al., 2013). For
example, increased spontaneous and burst firing of the VTA
DA neurons was found in some rodent models of depressionC
This is an open access article under the CC BY-N(Friedman et al., 2008; Krishnan et al., 2007); moreover, antide-
pressant fluoxetine can revert this increased activity (Cao
et al., 2010). These observations suggest that the high firing ac-
tivity of the VTA DA neurons is a salient characteristic of depres-
sion (Krishnan et al., 2007; Chaudhury et al., 2013) and that dys-
functions of the DA circuit of the VTA DA are responsible for
depression conditions (Chaudhury et al., 2013; Tye et al.,
2013). Interestingly, recent work also shows that activity of
VTA DA neurons regulates neuropathic pain (Huang et al.,
2020). Thus, gabapentin reversed nerve-injury-related depres-
sion behavior and increased activity of VTA DA neurons (Fu
et al., 2018). However, it is still unknown if the VTA DA neurons
are involved in comorbid depression in chronic pain.
The firing activity of the VTA DA neurons is regulated by the
input projections; moreover, the glutamatergic input appears
to be necessary for the burst firing activity of the VTA DA neurons
(Overton and Clark, 1997; Zweifel et al., 2009; Omelchenko et al.,
2009; Dobi et al., 2010). Prominent brain regions that receive or
send the VTA projections include nucleus accumbens (NAc),
dorsal raphe nucleus (DRN), medium prefrontal cortex (mPFC),
and lateral habenula (LHb). These networks of circuits have
been implicated in depression behaviors (Gunaydin et al.,
2014; Zhang et al., 2018; Yamada et al., 2013; Lammel et al.,




OPEN ACCESSalso interact with these networks. For example, the spino-para-
brachial circuits originate from the spinal dorsal horn and termi-
nate in the lateral and external medial parabrachial nucleus
(PBN) (Feil and Herbert, 1995). Populations of neurons in these
regions send out projections to the midbrain regions, such as
the amygdala and hypothalamus, which could be particularly
activated by noxious stimuli (Bernard et al., 1996). Additionally,
the midbrain DA neurons are known to acutely respond to bio-
logically salient peripheral stimuli (e.g., nociceptive) with short-
latency phasic bursts (Coizet et al., 2006; Maeda andMogenson,
1982). Nonetheless, little is known about the circuits and mech-
anisms linking the ascending nociceptive pathways and the DA
system in the midbrain and even less about potential mecha-
nisms of altered VTA DA neuron activity in chronic-pain-induced
depression.
In this study, we used pharmacology, electrophysiology,
neuron projection tracing, immunofluorescence, optogenetics,
and chemogenetics to elucidate midbrain circuits linking chronic
pain and depression and to systematically investigate the role of
the VTA DA neurons in the comorbid depression behavior in a tri-
geminal neuralgia model of chronic pain. We report a neural
network linking the spinal trigeminal subnuelcus caudalis
(SP5C) to the lateral PBM (LPBN) and the VTA DA neurons. We
further show that this network is necessary for the development
of depression-like symptoms associated with neuropathic pain
development and that this network can be targeted to dissociate
chronic pain and comorbid depression.
RESULTS
Chronic trigeminal neuralgia leads to depression-like
behavior and increased activity of the VTA DA neurons
To investigate the mechanisms for the comorbid depression
behavior in a chronic pain condition, we first established a tri-
geminal neuralgia mouse model of partial infraorbital nerve tran-
section (pIONT) (Figures 1A and 1B). The neuropathic pain devel-
opment in this model can be quantified as a frequency of specific
face-grooming behavior (Vos et al., 1994). This behavior
increased dramatically from day 1 after the pIONT surgery and
sustained throughout the experimental timeline of 28–31 days
(Figure 1C), indicating the neuropathic pain is chronic and persis-
tent in this model. In a sham control group of mice, which under-
went similar surgery except no transection of the nerve was per-
formed, no induced neuropathic pain behavior was observed
(Figure 1C). The following behavioral tests were performed at
weekly intervals (for 4 weeks in total) following pIONT: the tail
suspension test (TST), the forced swimming test (FST), the
open field test (OFT), the sucrose preference test (SPT), and
the social interaction test (SIT) under a subthreshold stress stim-
ulation. The body weight was also measured (Figures S1A–S1G).
In the TST and the FST that are often used in depression-like
behavior studies, an increased immobility time (indicative of
the depression-like behavior; Hao et al., 2019; Golden et al.,
2011) was observed at the 4th week (28th day) in the pIONT
mice in comparison with the sham group (Figure 1D; Figures
S1A and S1B). Importantly, the locomotion abilities of the pIONT
mice reflected by the traveling distance in the OFT remained un-
affected (Figure S1C), indicating that the surgery and associated2 Cell Reports 37, 109936, November 2, 2021pain did not affect locomotor activity as such. Hence, the
increased immobility time in the TST and FST is unlikely to reflect
a motor deficit associated with the surgery but instead is caused
by a depression-like phenotype. A transient increase in the ratio
of the time the mice spent at the central versus the peripheral
area in the OFT test was observed at 7 days after the surgery,
indicating a less anxious state of these mice; however, this result
was not observed at later time points (Figure S1D). It should be
noted that in the SPT, which is also often used as a test for
depression-like behavior (Liu et al., 2018), no difference was
observed between the pIONT and the sham mice (Figure S1E).
This finding is not entirely unexpected because not all depres-
sion-like behaviors are present in different animal models (Hao
et al., 2019). For SIT, we found a normal interaction ratio in
both the pIONT and sham mice (Figure S1F). No differences in
body weight between the pIONT and the sham mice were
observed (Figure S1G).
Accumulating evidence (Krishnan et al., 2007; Chaudhury
et al., 2013), including our own results (Li et al., 2017), suggest
that the DA neurons in the VTA play important roles in depres-
sion-like behavior. Specifically, depression-like behavior is often
associated with an increased burst firing of DA neurons in the
VTA (Krishnan et al., 2007; Chaudhury et al., 2013; Li et al.,
2017). To assess whether the depression-like behavior associ-
ated with pIONT neuropathic pain was also related to an
increased VTA DA activity, we first recorded the VTA DA neuron
firing in vivo and in vitro at the 28th–31st day after the pIONT sur-
gery (Figure 1A), which are at time points at which pIONT mice
already developed signs of depression-like behaviors. First, sin-
gle-unit recordings were performed from VTA DA neurons of
anesthetized mice; both the tonic and burst firing in these neu-
rons (Figure 1E) were increased in the pIONT mice, in compari-
son with the sham mice (Figure 1F). DA neurons were identified
by spike waveform (see STAR Methods). It should be noted
that no such increase was seen at 14 days after the surgery
(Figure S1H), when the depression-like behavior had not devel-
oped yet (Figures S1A and S1B). These findings indicate that
the depression-like behavior correlated temporally with the
increased firing of the VTA DA neurons. We also performed
in vitro cell-attached patch clamp recordings on the VTA brain
slices, and similarly, the firing of the VTA DA neurons was also
increased in the pIONT mice, as compared to sham animals
(28 days post-surgery); specifically, neurons in the lateral rather
than the medial VTA area displayed such an increased activity
(Huang et al., 2019; Figure 1G).
To summarize, these results suggest that the development of
the depression-like behavior after pIONT is temporarily corre-
lated with increased firing of the VTA DA neurons.
Inhibition of increased firing of the VTA DA neurons
reverses the depression-like behavior in the pIONTmice
To establish a direct link between the increased firing of the VTA
DA neurons and the depression-like behavior seen in the pIONT
mice, we tested if reducing the firing activity of the VTA DA neu-
rons would reverse the depression-like behavior. To this end, re-
tigabine (RTG), an opener of Kv7/KCNQ channels, was first used
to inhibit the VTA DA neurons. Antiexcitatory Kv7 channels are
expressed in VTA DA neurons, and RTG was shown to inhibit
Figure 1. Chronic trigeminal neuralgia induces the depression-like behavior and increases the firing activity of the VTA DA neurons
(A) Schedule for the pIONT (partial infraorbital nerve transection) procedure and subsequent experiments.
(B) Schematic of the trigeminal nerve anatomy, showing infraorbital branch and the pIONT ligation/transection point (red line).
(C) Summary for trigeminal neuralgia, quantified as the frequency of face-grooming behaviors after the pIONT (n = 10) or sham (n = 9) surgeries, respectively; ***p <
0.001 (two-way repeated-measures ANOVA; Bonferroni post hoc test).
(D) Summary of the immobility times in tail suspension test (TST; i), and the forced swimming test (FST; ii) at the 28th day after the pIONT operation (n = 10; ***p <
0.001; two-tailed t test).
(E) Example traces of in vivo single-unit recordings of tonic (left) and burst firing (right) recorded from the VTA DA neurons of the pIONT and the sham-operated
mice.
(F) Summarized firing frequency (i), number of bursts per minute (ii), and average number of spikes in a burst (iii); n = 13–15, **p < 0.01, ***p < 0.001, two-tailed
t test.
(G) Firing frequency of the VTA DA neurons recorded in vitro from the brain slices of the lateral (i) and the medial (ii) VTA; n = 5–7, *p < 0.05, two-tailed t test. See
also Figure S1.




Figure 2. RTG reduces the firing activity of the VTA DA neurons and alleviates the depression-like behaviors
(A) Schedule of the experimental procedures (left) and schematic illustration for drug delivery.
(B) Example recordings from the VTA DA neurons before and during the application of vehicle (ACSF, 0.4 ml) or RTG (200 mM, 0.4 ml), applied in sequence to the
same neuron. The recordings were made using in vivo single-unit recordings 28 days after the pIONT or sham operations.
(C) Histogram showing the time course of RTG-induced inhibition on the VTA DA neuron firing frequency.
(D) Summary data for experiments as those shown in (B). The frequencies were quantified at 5 min after the ACSF or RTG application (n = 8, ***p < 0.001, one-way
repeated-measures ANOVA with Bonferroni post hoc test).
(legend continued on next page)






OPEN ACCESSthese neurons (Li et al., 2017). We implanted into VTA a multi-
channel pipette, which was used to record the single-unit firing
of VTA DA neurons, as well as for local RTG (or vehicle) delivery
(Figure 2A). Application of vehicle control (artificial cerebrospinal
fluid [ACSF]) did not affect the firing of the VTA DA neuron; RTG
(200 mM, 400 nL) on the other hand significantly and reversibly
reduced the firing activity of the VTA DA neurons (Figures 2B–
2D). A transient decrease in the firing frequency caused by the
pressure from the drug-delivering pipette could be seen immedi-
ately following the drug application in some recordings (e.g., in
Figure 2C); this artifact quickly recovered, followed by a persis-
tent prominent inhibition of the firing by RTG (Figure 2C). Impor-
tantly, not only the total firing frequency but also the burst firing of
the VTADAneuronswas reduced in the pIONTmice. Not surpris-
ingly, the firing of the VTA DA neurons in the shammice was also
reduced by RTG (Figure 2E). We next applied RTG through a
cannula implanted in the VTA and evaluated the depression-
like behavior in the pIONT mice. The immobility time in the TST
was first measured in both the sham and the pIONT mice at
28–31 days after surgery; at 24 h after the first test, RTG
(200 mM, 400 nL) or ACSF was applied, and 15 min later, the
TST was repeated. As expected, pIONT mice developed the
depression-like behavior, manifested by increased immobility
time in the TST; however, it was reversed by RTG (Figure 2Fi).
Of note, RTG did not significantly affect the immobility time of
the TST in the sham mice (Figure 2Fii).
Another important observation was that VTA-delivered RTG
did not affect the pIONT-induced neuropathic pain behavior.
Indeed, the face grooming intensity was not affected by local
application of RTG into the VTA (Figure S2A). Furthermore, we
also tested the effect of RTG on nocifensive behaviors that orig-
inated not from the trigeminal nerve but from the spinal nerve; in
this regard, VTA-applied RTG did not affect the sensitivity of
naive mice to noxious mechanical and thermal stimulation
applied to the hind paws (Figures S2B and S2C). Thus, the
data suggest that dampening the firing activity of the VTA DA
neurons reduces chronic-pain-associated depressive behavior
but not the pain itself. Here and in other similar experiments,
we did not perform FST, as cannulated animals struggled to
keep their heads above the water.
Specific manipulation of VTA DA firing activity affects
the depression-like behavior of the pIONT neuropathic
pain mice
The above results from the pharmacological tool (RTG),
although strongly indicative, did not rule out the possibility
that RTG could affect the depression-like behavior indirectly
through targets outside the VTA DA neurons. To exclude this
possibility, a more specific targeted modulation of the VTA DA
neurons was needed. To this end, a chemogenetics strategy
was used first. AAV-DIO-hM4D-mCherry (AAV, adeno-associ-
ated virus; DIO, cre-on) viral particles were injected into the(E) Summary data for the effects of RTG on the firing frequency (i), burst/min (ii), an
5–10, *p < 0.05, paired t test).
(F) Summary data for the effects RTG and ACSF on the immobility time in the TST
given through the cannula implanted into the VTA (n = 8, **p < 0.01, one-way repe
before and 15 min after the infusion of either RTG or ACSF, with an interval of 24VTA of a dopamine transporter (DAT; specific marker of DA neu-
rons)-Cre mouse line, and the firing of the VTA DA neurons was
selectively inhibited by activation of hM4D receptor, expressed
specifically in the DA neurons, by an artificial ligand, clozapine
N-oxide (CNO). In this series of experiments, the pIONT surgery
was performed on these DAT-Cre mice that were VTA injected
with either the AAV-DIO-hM4D-mCherry or AAV-DIO-mCherry
(control) viral particles at the 21st day post-surgery (Figure 3A).
Immunofluorescence results confirmed the specific expression
of the viral cargo in the VTA DA neurons (Figure 3B). One
week later (28 days post-surgery), the TST was performed on
these mice before and 15 min after the intraperitoneal (i.p.) in-
jection of CNO (3.3 mg kg1) or vehicle (saline). At 24 h, later
the FST was carried out on the same animals under same con-
ditions as the TST. As shown in Figure 3C, CNO (but not vehicle)
significantly reduced the immobility time in both the TST and the
FST in the AAV-DIO-hM4D-mCherry-injected mice but not in the
control-virus-injected mice (Figure 3D). Importantly CNO did not
affect the immobility time in the TST and FST in the sham-oper-
ated mice which expressed hM4D in the VTA DA neurons (Fig-
ure S3A), and similar to RTG, CNO did not affect the pIONT-
induced pain behavior (face grooming) (Figure S3B). These
data again indicate that selective inhibition of VTA DA neurons
reduced pain-associated depression but not the pain itself.
Next, we tested if activation of the VTA DA neurons in naive
mice would induce the depression-like behavior. Viral particles
carrying the gene for the excitatory DREADD receptor hM3D
(AAV-DIO-hM3D-mCherry; Figure 3E) were delivered to the
VTA of the naivemice, and tests were carried out before and after
the application of CNO. In contrast to the inhibitory hM4D,
expression of the hM3D would enable CNO to excite the VTA
DA neurons. The immobility time in both the TST and FST was
elevated after CNO administration in the AAV-DIO-hM3D-
mCherry-injected mice (Figure 3F) but not in the AAV-DIO-
mCherry (control)-injected mice (Figure 3G). Similar to inhibitory
hM4D, activation of hM3D also did not affect the pain behavior of
the pIONT mice (Figure S3C).
Additionally, an optogenetic strategy was also used to activate
VTA DA neurons. In this case, AAV-DIO-ChR2-mCherry viral par-
ticles were delivered to the VTA of the DAT-Cre mouse line (Fig-
ure 3H). Activation of the ChR2 in the VTA DA neurons with the
475-nm laser illumination (by the VTA-implanted optical guide)
also increased the immobility time in the TST (Figure 3I); this ef-
fect was not seen in the mice that received the control virus
(AAV-DIO-mCherry; Figure 3J). The above chemogenic and op-
togenetic results lend further support to our hypothesis that the
depression-like behavior developing in the pIONT mice is
directly caused by an increased firing activity of the VTA DA
neurons.
It should be noted however that optical stimulation of DA neu-
rons may be acutely rewarding, and this could complicate the
interpretation of the behavioral outcome of the TST test. Thisd spike/burst (iii) under in the pIONT-operated and the sham-operatedmice (n =
at 28 days after the pIONT or the sham operations. RTG (200 mM, 0.4 ml) was
ated-measures ANOVA with Bonferroni post hoc test). The TST was performed
h. See also Figure S2.
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OPEN ACCESSissue should possibility be tested in a more directed experi-
mental design in a future study.
Neuronal circuit linking VTA with LPBN
Because neuropathic pain is associated with the depressive
phenotype, a link between the neural pathways of neuropathic
pain and the VTA DA neurons, which control the emotions/
mood, must exist. Thus, next we aimed to establish the neuronal
circuits linking these two neurological phenomena. First, we
used the c-Fos expression as an indicator of neurons, activated
by the pIONT surgery. Immunofluorescence staining of c-Fos
was performed in whole-brain slices from the pIONT mice and
the shamcontrol mice at the 28th day after the surgery. Increased
c-Fos immunoreactivity was seen in themedial habenula, the lat-
erodorsal tegmental nucleus, the ventromedial hypothalamic nu-
cleus, the dorsomedial hypothalamic nucleus, the spinal trigem-
inal tract, median raphe nucleus, the locus coeruleus, and not
surprisingly the VTA. Noteworthy, the spinal trigeminal nucleus
caudalis (Sp5C), which is the nucleus receiving afferent input
from the trigeminal ganglion (TG) (Edvinsson et al., 2020), and
the LPBN that has been shown to be involved in the chronic
pain conduction pathway were also labeled (Figure S4; Sun
et al., 2020). A detailed c-Fos expression profile of pIONT and
sham animals is listed in Table S1 (supplemental information).
It should be noted that neural pathways that counteract the
chronic pain could also contribute to the observed c-Fos
activation.
To confirm a direct link between the VTA and the potential
upstream sites activated by the pIONT injury, we traced the neu-
rons projecting to the VTA by using retrograde labeling with ret-
robeads and, later, with Cre-dependent viral labeling (AAV-DIO-
GFP) (Figures 4A–4C). Whole-brain images were first taken to
track regions, which had been labeled by the VTA-injected retro-
beads; multiple regions were found to have projections to the
VTA (Figure 4B). For the theme of this study, we next focused
on the LPBN, which (1) was identified as one of the regions
sending the projections to the VTA (Figure 4B); (2) was activated
by the pIONT surgery (Figure S4); and (3) has been reported to be
involved in the development of neuropathic pain (Huang et al.,
2019), including trigeminal neuralgia (Rodriguez et al., 2017).
We then used a Vglut2-Cremouse line, in which Cre is expressedFigure 3. Specific manipulations with the VTA DA neuron activity alter
(A) Specific inhibition of the VTA DA neuron activity was realized with the use of c
DA neurons through the DAT-controlled Cre activity; schematic depicts the sche
(B) Top, schematic illustrating the injection of the viral construct carrying the hM4
into the VTA of the DAT-Cre mice (21 days after the pIONT operation). Bottom, m
(4’,6-diamidino-2-phenylindole) labeling is in blue.
(C and D) Specific inhibition of the VTA DA neurons in the pIONT mice reduced de
injected (C) and the AAV-DIO-mCherry-injected (D)mice in the TST (i) or the FST (ii)
i.p.); there was a 24-hr interval between the tests (n = 7, **p < 0.01, ***p < 0.001, o
t test [D]).
(E) Specific activation of the VTA DA neurons was achieved with the use of the
controlled Cre activity (DAT-Cre mice); specific expression of hM3D in the VTA D
(F and G) The mice injected with the hM3D-carrying virus (F) and with the contr
quantified (n = 6, ***p < 0.001, paired t test).
(H) Optogenetic activation of the VTA DA neurons in the naive mice. AAV-DIO-Ch
VTA of DAT-Cre mice. The ChR2 was activated by a 475-nm laser through an im
(I and J) The immobility time in the TST of mice with (I) and without (J) ChR2 expre
on; n = 8, ***p < 0.001, paired t test. See also Figure S3.under control of a glutamatergic neuron marker, Vglut2 (Todd
et al., 2003). Thesemicewere VTA injectedwith the viral particles
carrying Cre-dependent GFP (AAV-DIO-GFP); retrobeads were
also injected simultaneously. We then evaluated the appearance
of retrogradely labeled neuron somata in the LPBN. As shown in
Figure 4C, neurons labeled with both GFP and retrobeads were
clearly visible in the LPBN (Figure 4C, arrowheads). Of note,
most of the neurons positively labeled with retrobeads (labeling
all LPBN-to-VTA projecting neurons) were also labeled with
GFP (labeling glutamatergic LPBN-to-VTA projecting neurons),
indicating that most of the LPBN neurons projecting to the VTA
were glutamatergic neurons.
LPBN-VTA projections regulate the depressive-like
behavior
To test if the above-identified LPBN-VTA glutamatergic projec-
tions are involved in regulation of the depression-like behavior,
we first used local VTA application of glutamatergic antagonist
AP-5 to block the glutamatergic input to the VTA, and the effect
of this maneuver on the depression-like behavior was observed.
AP-5 (200 mM, 400 nL) applied locally to the VTA of the pIONT
mice 28 days after the surgery through the multi-channel pipette
(Figure 4D) reversibly reduced the firing activity of the VTA DA
neurons (Figure 4E), including the total firing frequency and the
burst activity (Figure 4F). At the same concentration and volume,
AP-5 (but not the vehicle, ACSF) reduced the immobility time in
the TST (Figure 4G). On the other hand, AP-5 did not affect the
immobility time in the sham-operated mice (Figure S5Ai). Similar
to RTG chemogenic and optogenetic inhibition of VTA DA neu-
rons, AP-5 also did not affect the pain behavior (face-grooming
time) in the pIONT mice 28–31 days after the surgery (Fig-
ure S5Aii). These experiments suggest that blocking excitatory
glutamatergic input to VTA selectively inhibits depressive-like
behavior associated with chronic pain but not the pain itself.
In the above experiments, AP-5 abolished all types of glutama-
tergic transmission, including the input from distant projections
or from local VTA circuits. To specifically test the function of glu-
tamatergic projections from LPBN to the VTA DA neurons, the
glutamatergic LPBN-VTA pathway was specifically inhibited us-
ing the inhibitory opsin NpHR. In these experiments, the pIONT
surgery was performed on the Vglut2-Cre mice, and the viraldepression-like behaviors
hemogenetic activation of the hM4D receptor selectively expressed in the VTA
dule of experimental procedures.
D receptor (AAV-DIO-hM4D-mCherry) or the control virus (AAV-DIO-mCherry)
Cherry fluorescence was clearly visible in the VTA DA neurons; nuclear DAPI
pression-like behaviors. The immobility time of the AAV-DIO-hM4D-mCherry-
weremeasured before and 15min after the administration of CNO (0.33mg/kg,
ne-way repeated-measures ANOVA with Bonferroni post hoc test [C] or paired
hM3D receptor selectively expressed in the VTA DA neurons through DAT-
AT neurons was confirmed by the co-expressed mCherry (bottom panel).
ol virus (G) were subjected to TST (i) or FST (ii), and the immobility time was
R2-mCherry or AAV-DIO-mCherry (control) viral particles were injected into the
planted optical fiber.
ssion were measured under 475-nm (20 Hz, 5 pulses per 10 s) light off and light
Cell Reports 37, 109936, November 2, 2021 7
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OPEN ACCESSparticles carrying Cre-dependent NpHR (AAV-DIO-NpHR-eYFP;
NpHR, Halorhodopsin; eYFP, a mutation of yellow fluorescent
protein) were injected into the LPBN. The LPBN-VTA glutamater-
gic projections were then specifically inhibited by activation of
the NpHR at the nerve terminals in the VTA through the 590-
nm laser illumination delivered through the implanted light guide
(Figures 5A and 5B). The viral construct was well expressed in
the LPBN glutamatergic neuron somata and at the projection ter-
minals around the VTA DA neurons (Figure 5C). The immobility
time in the TST was significantly reduced in pIONT mice upon
optogenetic stimulation (Figure 5D), suggesting that inhibition
of the LPBN-to-VTA glutamatergic projections was able to
reverse the depressive-like behavior of the pIONT mice. Howev-
er, in a similar setting, activation of NpHR did not affect the
immobility time in the TST performed on sham mice (Figure S5B
and S5C).
A similar strategy was also applied on the naive mice, except
that the inhibitory NpHR was replaced with the excitatory ChR2
(AAV-DIO-ChR2-mCherry). In this case, the LPBN-to-VTA gluta-
matergic input was activated to test if it would confer the naive
mice with the depression-like behavior (Figures 5E–5H). Indeed,
illumination of the VTA with the 475-nm laser significantly
increased the immobility time in mice injected with the ChR2-
carring virions (Figure 5Hi) but not control virions (Figure 5Hii).
A direct Sp5C-LPBN-VTA circuit controls the
depression-like behavior in the mice with chronic
trigeminal neuralgia
In our c-Fos experiments (Figure S4; Table S1), the increased
c-Fos fluorescence was also evident in the Sp5C, which is a nu-
cleus relaying the pain signals from the TG to the higher brain
centers (Hargreaves, 2011; Pradier et al., 2019). We reasoned
that there could be a circuit connecting the Sp5C with the VTA,
which can possibly involve projections through the LPBN
because the link between the Sp5C and the LPBN has been re-
ported (Edvinsson et al., 2020). To establish if such a connection
exists, we first used the retrobeads and the AAV-DIO-GFP in-
jected into the LPBN of Vglut2-Cre mice. Two weeks after the in-
jection, the retrobeads and GFP signals were indeed clearly
visible in the Sp5C (Figures 6A and 6B). To test if there are direct
monosynaptic projections from the Sp5C to the LPBN and from
the LPBN to the VTA, we used the trans-monosynaptic retro-
grade labeling approach. To this end, two viral constructs car-Figure 4. Glutamatergic projections from LPBN to VTA control depres
(A) Retrobeads (100 nL) and Cre-dependent virus AAV-DIO-GFP were injected to
and retrograde tracing in the LPBN.
(B) Retrobead fluorescence in an image from a 30-mm coronal brain section from th
by the retrobeads are shown with dotted ellipses.
(C) Higher-magnification images showing the retrobeads and GFP fluorescence
panel (arrowheads). The area indicated by the white square is shown in the botto
(D) Experimental schedule (left) and schematic of a cannula placement (right) for th
the VTA at 21 days after the pIONT/sham operation.
(E) Example traces of single-unit recordings showing firing of the VTA DA neurons
the time course for the effect of AP-5 on the firing frequency.
(F) Summary data for effects of AP-5 on firing frequency (i), burst number/min (ii), a
t test.
(G) Summary data for effects of AP-5 and the vehicle (ACSF) on the immobility time
24 h between ACSF and AP-5; n = 14, ***p < 0.001, one-way repeated-measurerying AAV-DIO-TVA-tdTomato and AAV-DIO-RVG were injected
into the LPBN of Vglut2-Cre mice as helpers to specifically ex-
press these rabies virus (RV) components in the glutamatergic
cells projecting from the LPBN to the VTA and to enable future
RV infection and trans-monosynaptic tracing (Suzuki et al.,
2020) to the Sp5C. Four weeks later, the replication-deficient
RV (RV-ENVA-DG-eGFP) was injected into the VTA (Figure 6C).
This maneuver enables simultaneous tracing of direct projec-
tions from the LPBN to the VTA and monosynaptic projections
from the Sp5C to the LPBN. After one more week, the GFP
was identified at the Sp5C (Figure 6D), whereas tdTomato was
detected in VTA. These results confirmed the existence of a
direct Sp5C-to-LPBN-to-VTA circuit.
Next, we tested if this Sp5C-LPBN-VTA circuit was involved in
the depression-like behavior of the pIONT neuropathic pain
mice. The pIONT surgery was performed on the Vglut2-Cre
mice, and the AAV-DIO-NpHR-eYFP was injected to the Sp5C,
which enabled the glutamatergic-neuron-specific expression of
NpHR in the projections from the Sp5C to the LPBN (Figure 6E).
After one week, the NpHR-eYFP was clearly detectable in the
terminals of glutamatergic Sp5C projections in the LPBN. These
terminals were inhibited by a laser light delivered through the op-
tical fiber implanted into the LPBN (Figures 6F and 6G). In AAV-
DIO-NpHR-eYFP-injected mice, light stimulation significantly
reduced immobility time in the TST (Figure 6Hi), an effect that
was not seen in mice injected with AAV-DIO-eYFP (control; Fig-
ure 6Hii). These experiments confirmed that the Sp5C-LPBN-
VTA circuit is a functional pathway producing depressive
behavior in chronic pain states.
DISCUSSION
In this study, we present cellular, anatomical, and functional ev-
idence for the existence of a neuronal circuit linking the Sp5C,
LPBN, and VTA. We show that this pathway mediates the devel-
opment of depressive behavior comorbid to chronic cranial
neuropathic pain. The major findings of this study include the
following: (1) glutamatergic projections from the Sp5C innervate
the glutamatergic neurons in the LPBN, which project to the VTA
and modulate the activity of the DA neurons in this nucleus. (2)
This Sp5C-LPBN-VTA circuit is activated under a state of chronic
neuropathic pain, which ultimately results in an increased firing
activity of the VTA DA neurons. (3) Overactivity of the VTA DAsion-like behaviors
the VTA of Vglut2-Cre mice to visualize a Vglut2-controlled expression of GFP
e ventral side at Bregma5.34mm. The brain regionsmost prominently labeled
in the LPBN neuron. Co-labeling of GFP and retrobeads is indicated in the top
m panel with higher magnification.
e local application of the NMDA blocker AP-5. The cannula was implanted into
before and during AP-5 (200 mM, 300 nL) application (left). Shown on the right is
nd spike number/burst (iii); n = 10–12, ***p < 0.001, **p < 0.01, *p < 0.05, paired
in the TST. The TST was performed 15min after application, with an interval of
s ANOVA with Bonferroni post hoc test. See also Figures S4 and S5.
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Figure 5. Selective manipulations with the glutamatergic LPBN-VTA projections alter the depression-like behaviors
(A) Experimental schedule.
(B) Schematic of viral labeling. AAV-DIO-NpHR-eYFP/AAV-DIO-eYFP (200 nL) virions were injected into the LPBN of the Vglut2-Cre mice bilaterally at 21 days
after the pIONT operation, and an optical fiber was implanted in the VTA. The 590-nm laser was used to activate NpHR.
(legend continued on next page)






OPEN ACCESSneurons underlies the depression behavior developed under a
state of chronic neuropathic pain. (4) Pharmacological or genetic
interventions inhibiting the firing of the VTA DA neurons reverse
the depressive behaviors, thus ‘‘uncoupling’’ chronic pain from
comorbid depression. With a high proportion of depression
symptoms seen in patients with chronic pain (Cheng et al.,
2017; Tang et al., 2016) and a reciprocal interaction between
depression and chronic pain (Bair et al., 2003; IsHak et al.,
2018), our findings provide a framework for the underlying net-
works and mechanisms linking these two neurological phenom-
ena. These findings may also aid the diagnosis and treatment of
these debilitating conditions, which often present a challenge in
clinical practice (Bair et al., 2003; IsHak et al., 2018).
Although it has long been hypothesized that neural processing
of chronic pain and its affective aspects, including those leading
to depression, could share common neural pathways andmech-
anisms, they have not been clearly established. Here, we are
filling a part of this void by establishing a VTA-DA-neuron-
centered pathway, which orchestrates the depression behavior
in a chronic pain condition. Recent evidence suggests that the
altered firing activity, especially the burst firing of the VTA DA
neurons, which encodes the release of dopamine (Gonon,
1988; Grace, 1991), directly governs the depression behavior
(Krishnan et al., 2007; Chaudhury et al., 2013; Tye et al., 2013)
and regulates neuropathic pain (Huang et al., 2020). The activity
of the VTA DA neurons is under complex control by both the
intrinsic as well as the regulatory activity (Overton and Clark,
1997; Zweifel et al., 2009; Omelchenko et al., 2009; Dobi et al.,
2010). In this study, we provide evidence that there is a direct
pathway linking Sp5C with LPBN and LBPN with the VTA DA
neuron system. The Sp5C, in turn, receives direct input from
the trigeminal nucleus (Sessle, 2000), where nociceptive signals
produced by peripheral nerve injury originate. Multiple pieces of
evidence, including pharmacological, neuron projection tracing,
and chemo- and optogenetic results, presented here strongly
support this claim. Thus, the experiments using the RV to trace
trans-monosynaptic connections suggest that the connection
between the Sp5C and the LPBN and between the LPBN and
the VTA must indeed be direct (Figure 6). Under the condition
of persistent noxious input (as in the case of the pIONT neuro-
pathic pain model), the Sp5C-LPBN-VTA pathway must be
persistently activated, which was manifested by the increased
c-Fos expression in the Sp5C, the LPBN, and the VTA (as well
as in some other brain areas). The persistent activation of this
pathway is likely to exert a plastic effect on the VTA DA neurons
and the downstream targets of the VTA DA neuron projections,
which ultimately establish a basis for the observed depression
behavior. This notion is supported by the observation that the(C) eYFP fluorescence confirmed the expression of NpHR at the projection termin
cell bodies in VTA (bottom panel).
(D) Summary data for effects of the 590-nm laser illumination (constant) on the im
illumination on the mice at 28 days after the pIONT surgery; n = 8, **p < 0.001, p
(E–G) Selective activation of the glutamatergic neurons in the LPBN projecting to
AAV-DIO- ChR2-mCherry/AAV-DIO-mCherry (200 nL) virions were injected bilat
implanted into the VTA. A 475-nm laser was used to activate ChR2 (F). (G) Exp
glutamatergic neurons from the LPBN (top panel) and around the neuronal cell b
(H) Activation of ChR2 with 475-nm illumination in the VTA increased the immob
control (ii) mice; n = 10, ***p < 0.001, paired t test. See also Figures S5 and S6.depression behavior develops with a considerable delay (over
3weeks) after the pIONT surgery, long after the onset of the pain-
ful behavior that normally is already evident the next day after the
surgery. This delayed development of depression behavior was
also reported in a different neuropathic model, namely, spared
nerve injury (SNI) (Zhou et al., 2019).
A direct glutamatergic link from the Sp5C to the LPBN and to
the VTA DA neurons has not been described before, although
monosynaptic inputs to the VTA DA neurons from the LBPN
were demonstrated (Watabe-Uchida et al., 2012; Ogawa et al.,
2014; Beier et al., 2015), including a glutamatergic projection
from the LPBN to the VTA that has just been reported to control
pain behavior (Yang et al., 2021). Our current study ascribes the
LBPN glutamatergic neurons projecting to the VTA DA neurons
with a functional role in mediating chronic-pain-induced depres-
sion behavior. Recently, the glutamatergic neurons in the PBN
were found to be responsible not only for relaying basal nocicep-
tion but also for processing neuropathic pain in a model of com-
mon peroneal nerve (CPN) ligation (Sun et al., 2020). Our data
further extend this line of evidence by adding a trigeminal neural-
gia neuropathic pain model to the list; collectively, these findings
suggest that the LPBN could be a common relay pathway for the
neuropathic pain and depression comorbidity.
A different projection pathway was recently described for the
depression associated with SNI-induced neuropathic pain (Zhou
et al., 2019). This pathway involves the 5-hydroxytryptamine (5-
HT) neurons in the DRN to somatostatin (SOM)-expressing and
non-SOM interneurons in the central nucleus of the amygdala
(CeA), which then project directly to the LHb, an area known for
its involvement in depression (Yang et al., 2018). Yet, it is tempting
tospeculate that thispathwaymayultimatelydetour to theVTADA
neuronsbecause dense direct projections fromboth theDRNand
the LHb to the VTA DA neurons have been described (Lammel
et al., 2012; Watabe-Uchida et al., 2012; Ogawa et al., 2014).
Thus, these midbrain monoamine circuits regulated by the inputs
from the pain pathways emerge as central integration hubs for the
processing of pain and the affective behaviors.
The LPBN is known for involvement in both somatic and
craniofacial pain transmission (Sun et al., 2020; Hermanson
and Blomqvist, 1996). Importantly, craniofacial stimuli appear
to be stronger activators of the nociceptive LPBN (Hermanson
and Blomqvist, 1997), and a stronger affective aspect of the
craniofacial pain was described, as compared to pain arising
from the spinal somatosensory stimuli (Schmidt et al., 2019).
One reason for these differences could be the presence of a
dual pathway from the TG, namely, the TG-LPBN pathway and
the TG-Sp5C-LPBN pathway. In contrast, a single indirect
pathway from the dorsal root ganglion (DRG), namely, theals of the glutamatergic neurons from the LPBN (top panel) around the neuronal
mobility time in the TST. The TST was performed before and during the laser
aired t test.
the VTA DA neurons increased the immobility time of the TST in the naive mice.
erally to the LPBN of the naive Vglut2-Cre mice (E), and an optical fiber was
ression of the ChR2 (visualized by mCherry) at the projection terminals of the
odies in VTA (bottom panel).
ility in the TST in the ChR2-expressing (i) but not in the non-ChR2-expressing
Cell Reports 37, 109936, November 2, 2021 11
(legend on next page)






OPEN ACCESSDRG-spinal dorsal horn-LPBN (Rodriguez et al., 2017), was
found for spinal somatosensory transmission. Future studies
shall reveal whether this differential affective processing of spinal
versus trigeminal pain involves distinct subpopulations of the
LBPN neurons or is a stimulation-intensity-coded phenomenon.
Another important notion is that although the depression-like
behavior in the pIONT mice was clearly caused by neuropathic
pain from the trigeminal nerve injury, we have strong reasons
to believe that depression and pain are controlled and processed
separately in the brain. Thus, various pharmacological, chemo-
genetic, and optogenetic manipulations with VTA DA neuron ac-
tivity, which reversed the depression-like behaviors, did not
affect the neuropathic pain behaviors. This is further supported
by the observation that the depression-like behavior developed
with a significant delay after the pIONT procedure, long after
the pain behavior was established. Thus, chronic pain and
depression, although inter-related, clearly are distinct neurolog-
ical phenomena; moreover, as we show in this study, pain and
comorbid depression can be disassociated by manipulations
with the Sp5C-LPBN-VTA pathway.
An important observation from this study was that the depres-
sion behavior developed in the pIONT neuropathic pain mice
could be reversed by pharmacological intervention using a
Kv7/KCNQ channel opener, RTG. When infused directly into
the VTA, RTG reduced the firing activity of the VTA DA neurons,
and, consistent with previous studies (Li et al., 2017; Friedman
et al., 2016; Tan et al., 2020), led to the reversal of the depression
behavior. This result potentially opens a window of opportunity
for RTG or similar drugs to be used for the treatment of the
depression symptoms comorbid to chronic pain. Importantly,
RTG and other Kv7 openers have analgesic efficacy, most likely
acting through the peripheral nervous system (Du et al., 2014;
Hayashi et al., 2014). Thus, these drugs could be beneficial for
the treatment of both depression and pain.
It should also be emphasized that the relationships between
chronic pain and depression are complex; not only could chronic
pain trigger depression but also depression is a major modulator
of the chronic pain states (Simon et al., 1999). This mutual pene-
tration is best reflected in the fact that some antidepressants are
the first-line drugs for the treatment of neuropathic pains (Obata,
2017; Finnerup et al., 2010). We believe that the present study
sheds light on the intricate relationships between chronic painFigure 6. Direct glutamatergic projection pathway linking Sp5C, LPBN
(A and B) Projections from the Sp5C to the LPBN identified through retrograde lab
mice (A). Co-staining with retrobeads and GFP is visible in multiple neurons in th
(C) Schematic for the trans-monosynaptic retrograde projection tracing of the S
jection are indicated. The Cre-dependent constructs were injected into the Vglut
(D) Visualization of the expression of tdTomato and GFP in the VTA, the LPBN, an
somata in the LPBN (middle panel) and in presumed projection terminals (from LPB
(bottom panel). This pattern indicates a restricted expression of the tdTomato in t
the VTA, was clearly expressed in the glutamatergic neuron somata in the Sp5C (b
neurons in the Sp5C and the LPBN that projected to the VTA.
(E) Schematic for testing the effects of Sp5C-LPBN pathway inhibition on the de
(F) Schematic indicating viruses used and injection and illumination sites. The vi
21 days after the pIONT operation, and an optical fiber was implanted in the LPB
(G) Following Sp5C injection, NpHR was expressed at the terminals of Sp5C-L
rescence).
(H) Summary data for the effects of inhibiting the glutamatergic projections from th
with a 590-nm laser reduced the immobility time in NpHR expression mice (i) buand depression by identifying a neural pathway feeding into
depression circuits from the pain matrix; however, the full
complexity of these relationships is yet to be discovered and
should be investigated in future studies.Limitations of the study
In this study, only male mice were used, mainly due to the use of
the social defeat depression model that excludes the possibility
of using female mice. The sex hormones could have a significant
effect on the pain responses, the depression behaviors, and the
underlying mechanisms. Thus, interpretation of the current re-
sults in a more general scope should be carefully considered.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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celrep.2021.109936.d VTA governs the chronic-pain-induced depression behaviors
g. Retrobeads and AAV-DIO-GFP were injected in the LPBN of Vglut2-Cre
p5C (B).
-LPBN-VTA pathway. Viruses used, the injection sites, and the time of in-
re mice, thus restricting the expression to the glutamatergic neurons.
e Sp5C. The tdTomato was prominently visible in the glutamatergic neuron
in the VTA (top panel, arrowheads); tdTomato was not detected in the Sp5C
lutamatergic neurons of the LPBN projecting to the VTA. GFP, injected into
m panel), indicating amonosynaptic connection between the glutamatergic
sion behaviors by using optogenetic manipulation.
s (200 nL) were injected bilaterally to the Sp5C of the Vglut2-Cre mice at
a 590-nm laser light was used for NpHR stimulation.
-projecting glutamatergic neurons in the LPBN (visualized by eYFP fluo-
p5C to the LPBN on the immobility time in the TST; illumination of the LPBN
t in the control mice (ii); n = 8, ***p < 0.001, paired t test.
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OPEN ACCESSEXPERIMENTAL MODEL AND SUBJECT DETAILS
The following mouse strain was used for this study: C57BL/6J – The Jackson Laboratories, Cat#: 000664; DAT-IRES-cre – The Jack-
son Laboratories, Cat#: 000664; Vglut2-ires-Cre – The Jackson Laboratories, Cat#: 000664. Male and female adult mice (6-10 weeks
old) were used for all experiments. All procedures and experiments were approved by and done in accordance with the policies of
Animal Care and Use Committee at Hebei Medical University and before and after any procedures, the mice were housed separately
with access to water and food (provided by The Experimental Animal Center of Hebei Province) ad libitum, under controlled temper-
ature (23–25 C), humidity and lighting (12:12 h light–dark cycle). In all behavioral experiments, animals were allowed to adapt to the
local environment for at least 1 day prior to experimentation. Male mice were used because of the social defeat depression model we
used, as it is only suitable for male mice (Golden et al., 2011). Mice were housed separately to avoid aggressive behavior and to pro-
tect animals after the surgery or device implantation.
METHOD DETAILS
Animal models of neuropathic pain
Mice were anesthetized with pentobarbital sodium (50 mg/kg, i.p) before the pIONT (partial infraorbital nerve transection) operation.
The infraorbital nerve, a branch of the trigeminal nerve emerging out of suborbital foramen and innervating the whisker pad, was
exposed from the incision of the skin between eye and nose. A 1-2 mm segment of the nerve tract was ligated, transected and
removed. The injury consists of both ligation and transection of most fibers in infraorbital nerve after passing through the foramen
infraorbital62. After the operation, the skin was sutured and disinfected with iodophor.
Cannula implantation and intracerebral drug infusion
Mice were anesthetized with pentobarbital sodium (50 mg/kg, i.p), a stainless-steel cannula guide with double parallel pipeline
(RWD Life Science, Shenzhen, China) was embedded into the ventral tegmental area (VTA) bilaterally (AP 3.08, LM ± 0.5, DP 4.2)
using a brain stereotactic frame (RWD Life Science, Shenzhen, China) and was secured to the skull surface by dental cement.
An injection cannula (0.2 mm protruded from the tip of the cannula guide, when plugged in) were connected to the cannula guide;a
syringe (1 ml, Hamilton Company, USA) pre-filled with the injection solution was mounted to connect the injection cannula with an
infusion pump (RWD Life Science, Shenzhen, China) set at a delivery rate of 100 nl/min (400 nL total volume). The intracranial infusion
of a drug was initiated by plugging the injecting cannula into the cannula guide. Drugs were applied as follows: retigabine (200 mM),
AP-5 (200 mM) and vehicle (artificial cerebrospinal fluid, ACSF), all in 400 nL total volume driven by an infusion pump at the rate
100 nL min-1.
Viral injections
Mice were anesthetized with pentobarbital sodium (50 mg/kg, i.p) and fixed in the stereotactic frame. After drilling the hole into the
skull surface, viral particles of 100-400 nLwas injected into the target nuclei through a calibrated glassmicroelectrode connected to a
syringe (1 ml, Hamilton Company, USA) using an infusion pump (RWD Life Science, Shenzhen, China) at the rate 50 nL min-1. The
specifics of the viral particles and purposes of the usage are explained below. The coordinates were defined as dorso-ventral
(DV) from the brain surface, anterior–posterior (AP) from bregma and medio-lateral (ML) from the midline (in mm).
For retrograde tracing, the Cre-dependent virions rAAV-Ef1a-DIO-EGFP-WPRE-hGH-Pa (AAV2/9, 5.85 3 1012 vg ml1, 100 nl)
were bilaterally injected into the VTA (AP, 3.08 mm; ML, ± 0.50 mm; DV, 4. 50 mm) and the LPBN (AP, 5.20 mm; ML, ±
1.25 mm; DV, 2.60 mm) of the Vglut2-Cre mice to confirm the projections PBL/VTA and Sp5C/PBL, respectively. For trans-
monosynaptic retrograde tracing, first two types of viruses, rAAV-Ef1a-DIO-RVG-WPRE-Pa (AAV2/9, 5.29 3 1012 vg ml1, 150 nl)
and rAAV-Ef1a-DIO-TVA-P2A-NLS-dTomato-WPRE-Pa (AAV2/9, 5.31 3 1012 vg ml1, 150 nl) were delivered to the PBL
(AP, 5.20 mm; ML, ± 1.25 mm; DV, 2.60 mm) of the Vglut2-Cre mice acting as helpers. After 3 weeks, modified rabies virus
RV-ENVA-DG-EGFP (R2.00 3 108 IFU ml-1, 200nl) was injected into VTA (AP, 3.08 mm; ML, ± 0.50 mm; DV, 4. 50 mm) to spe-
cifically infect the terminals of PBL/VTA neurons, due to the expression of TVA. Combined with rabies glycoprotein, trans-synaptic
retrograde labeling was achieved in Sp5C/PBL/VTA.
For optogenetics, rAAV-CAG-DIO-hChR2(H134R)-mCherry-WPREs-Pa (AAV2/9, 1.203 1012 vg ml1, 300 nl) or rAAV-CAG-DIO-
NpHR-eYFP-WPREs-Pa (AAV2/9, 1.203 1012 vg ml1, 300 nl) were delivered into the VTA (AP, 3.08 mm; ML, 0.50 mm; DV, 4.
50 mm), the LPBN (AP,5.20 mm;ML,1.25 mm; DV,2.60 mm) and the Sp5C (AP,6.60 mm;ML,1.75 mm; DV,3.50 mm) of
the respective mice used. The control construct for these injections was rAAV-CAG-DIO-mCherry-WPREs-Pa (AAV2/9, 1.20 3
1012 vg ml1, 300 nl). The optic fibers were implanted to the VTA (AP, 3.08 mm; ML, 0.50 mm; DV, 4. 50 mm) and LPBN
(AP, 5.20 mm; ML, 1.25 mm; DV, 2.60 mm).
For chemogenetics, rAAV-Ef1a-DIO-hM4D(Gi)/hM3D(Gq)-mCherry-WPREs-Pa (AAV2/9, 2.003 1012 vg ml1, 300 nl) or its control
rAAV-Ef1a-DIO-mCherry-WPREs-Pa (AAV2/9, 2.00 3 1012 vg ml1, 300 nl) were delivered into the VTA (AP, 3.08 mm; ML, ±
0.50 mm; DV, 4. 50 mm) of the mice used.
All the above viruses were provided by The BrainVTA (Wuhan, China).Cell Reports 37, 109936, November 2, 2021 e2
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Retrobeads (Lumafluor Inc, USA) were used for projection tracing. The injection procedures were same as for the viral injections
described above. For LPBN-VTA tracing, retrobeads (100 nl) were injected into the VTA (AP, 3.08 mm; ML, ± 0.50 mm; DV, 4.
50 mm). For Sp5C-LPBN tracing, retrobeads (100 nl) were injected into the LPBN (AP, 5.20 mm; ML, ± 1.25 mm; DV,
2.60 mm). The retrobeads and the fluorescence proteins (GFP, mCherry) carried by the viruses were visualized in the brain sections
by confocal microscopy using Nikon A1 (Nikon, Japan). For the brain-wide imaging, the coronal brain sections were cut at 30 mm
thickness every 200 mm of midbrain and hindbrain using a vibratome (VT1200S; Leica, Germany).
Optogenetics
Fiveminutes after virus injection, an optical fiber was implanted into the VTA (AP,3.08 mm;ML,0.50 mm; DV,4. 50 mm) and the
LPBN (AP, 5.20 mm; ML, 1.25 mm; DV, 2.60 mm) at the 21st day after surgery following virus injection and the fiber was fixed
with dental cement to the skull. The fiber was connected to a laser source (Changchun New Industries Optoelectronics Technology,
China) emitting blue (475 nm, 1.5 mW, 20 Hz, 5 pulses, interval 10 s) or yellow (590 nm, 5–8 mW, constant) light.
Chemogenetics
One week after the injection of AAV-DIO-hM4D(Gi)-mCherry/AAV-DIO-hM3D-mCherry or AAV-DIO-mCherry and before the behav-
ioral tests, clozapine N-oxide, CNO (3.3 mg kg-1, i.p.) was scheduled 15 minutes prior to the test.
Electrophysiology
Single-unit recording and local pressure drug administration
Single-unit recordings were used to record the spontaneous firing of the VTA dopaminergic (DA) neurons in vivo. Mice were anes-
thetized by pentobarbital sodium (50 mg/kg, i.p), fixed to the stereotactic frame and spontaneous firing was recorded in the VTA
(AP, 3.04 ± 0.12 mm; ML, 0.50 ± 0.10 mm; DV, 4.60 ± 0.40 mm). DA neurons were identified by their characteristic action
potentials: typically triphasic action potentials with a negative deflection: the action potential width from the start to the minimum
of R 1.1 ms, a characteristic long duration (> 2 ms) and a slow firing rate (< 10 Hz) (Ungless and Grace, 2012). It should be noted
that characteristics of action potential is not always a reliable way to differentiate the DA neurons from the GABA neurons (Margolis
et al., 2012). The presence of burst firing (as opposed to tonic firing) was identified by the following criteria: (i) the start of a burst was
registered when two consecutive spikes fired within 80 ms; (ii) the end of the burst was registered when the interspike interval (ISI)
exceeded 160 ms; and (iii) a neuron was considered as burst-firing if it fired at least one burst within 3 min. Electrical signals were
amplified and filtered by the Axoclamp 900A preamplifier and recorded by the Digidata 1440A AD converter (Molecular Devices,
USA); the data were analyzed by Clampfit 10.3 (Molecular Devices, USA).
The effect of Retigabine (200 mM), AP-5 (200 mM) and ACSF (vehicle) on the firing activity of the VTA DA neurons recorded using the
single-unit method was assessed 5 min after direct VTA local pressure (5–15 c) administration (PDES-02DX, NPI Electronic, Ger-
many). The effects of drugs were analyzed on the following parameters: (i) average firing rates (Hz); (ii) average number of bursts
per minute; (iii) average number of spikes in a burst.
Brain slice preparation and cell-attached patch clamp recording
Mice were anesthetized with pentobarbital sodium (100mg/kg, i.p) and perfused intracardially with ice-cold sucrose solution (in mM:
260 sucrose, 3 KCl, 26 NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 2 MgCl2, 10 D-glucose, saturated with 95%O2/5%CO2). Coronal midbrain
slices (200 mm) containing the VTA were cut by a vibratome (VT1200S; Leica, Germany) in ice-cold sucrose solution and then placed
in 37C oxygenated ACSF (in mM: 130 NaCl, 3 KCl, 26 NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 2 MgCl2, 10 D-glucose) for 30 min. The
slices were then left to recover at room temperature for about 90 min, transferred to the recording chamber and perfused with
oxygenated ACSF. Patch pipettes (3–5 MU, pulled from borosilicate glass capillaries by a four-stage horizontal puller, P97, Sutter
Instruments, USA) were filled with ACSF. The spontaneous firing activity was recorded in the cell-attached mode; electrical signals
were amplified and filtered by the Axoclamp 700B preamplifier and recorded by the Digidata 1440A AD converter (Molecular Devices,
USA); the data were analyzed by Clampfit 10.3 (Molecular Devices, USA).
Immunohistochemistry
Mice were anesthetized with pentobarbital sodium (100 mg/kg, i.p) and intracardially perfused with 20 mL cold PBS containing PFA
(4%). The brains were removed and post-fixed in PFA (4%) at 4C overnight and transferred into 30% sucrose solution at 4C for 48
hours dehydration. The tissue was then sectioned into coronal sections (40 mm thick) using a vibratome (Leica VT1200s, Germany).
The sections were incubated in blocking buffer (3%BSA, PBS with 0.3% Triton X-100) containing 10% donkey serum for 1 h at room
temperature, and then incubated with primary antibodies, including anti-DAT (1:500, rabbit, Abcam), anti-c-Fos (1:400, mouse, Ab-
cam), anti-Vglut2 (1:500, mouse, Abcam) at 4 C for 24 h, followed by the incubation with the corresponding fluorophore-conjugated
secondary antibodies (Jackson ImmunoResearch, USA) for 1 h at room temperature. Images were acquired using a Leica TCS SP5
confocal laser microscope (Leica, Germany) or Nikon A1 (Nikon, Japan) equipped with laser lines for 405 mm, 488 mm, 561 mm and
647 mm illumination.e3 Cell Reports 37, 109936, November 2, 2021
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Mice for testing were transferred to the testing room 24 h before the test for accommodation. During the testing session, the behavior
of the animals was recorded using a video tracking system and was subsequently analyzed offline. The experimenter was blinded to
group identity during the experiment and quantitative analyses.
Face-grooming
A mouse was placed into a translucent enclosure and left for 1 hour to adapt. Face-grooming actions were counted over a period of
2 min and quantified as frequency (strokes/min). The identification of face-grooming actions was judged by the position of the paw
over the facial region, following the method described in detail (Berridge, 1990).
Tail suspending test, TST
Mice were suspended by the tail using an adhesive tape at 1 cm from the tip of the tail sticking to a bar 50 cm above the plane. Each
mouse was tested only once for 6 min. The test was videotaped from the side and the immobility time of the animal was measured in
the last 4min of the test. Immobility was considered as a period of timewithout initiatedmovements, including passive swaying (Steru
et al., 1985).
Forced swimming test, FST
Mice were individually placed in a cylindrical container (12 cm diameter, 25 cm height) of 24 C water for 6 min. Mice swam for 6 min
under normal light and were videotaped from the side. The immobility time during the last 4 min of the test was counted. Immobility
was defined as time when animals remained floating or motionless with only movements necessary for keeping balance in the water
(Petit-Demouliere et al., 2005).
Sucrose preference test, SPT
Sucrose solution (1%) or drinking water was filled in 50 mL bottles with stoppers. All animals were singly housed and acclimatized to
two-bottle choice conditions for 12 h. After this, the positions of the tubes were interchanged and animals were left for further 12 h, at
the end of experiment fluid in both bottles was weighed.
Open filed test, OFT
Exploration of an open field arena (50 3 50 cm) was assessed during a 30-min test. A video-tracking system (Harvard Bioscience
(Shanghai) Co., Ltd., China) measured locomotor activity, as well as the time spent in the center (40 3 40 cm) and corners of the
test arena. The area was cleaned with 75% ethanol after each test to remove olfactory cues from the apparatus.
Mechanical and thermal sensitivity (hind paw)
Mechanical withdrawal threshold was measured by using Von Frey filaments (Stoelting Co, Chicago, IL, USA). Each mouse was
placed into a plastic cage with a wire mesh bottom. A single filament was applied perpendicularly to the plantar surface of the
hind paw for five times with an interval of 5 s. Positive response was defined as three clear withdrawal responses out of five appli-
cations. Filaments were applied in an up-and-down order according to a negative or positive response to determine the hind paw
withdrawal threshold.
Thermal withdrawal latency (Hargreaves method) in response to radiant heat (PL-200, Taimeng Co, Chengdu, China) was used
to evaluate thermal sensitivity. The intensity of the radiant heat stimulus was maintained at 15%. Mice were placed individually into
plexiglass cubicles placed on a transparent glass surface. The light beam from radiant heat lamp, located below the glass, was
directed at the plantar surface of hindpaw. The time from the onset of radiant heat stimulation to withdrawal of the hindpaw
(elapsed time) was recorded. Three trials with an interval of 5 min were made for each mouse, and scores from three trials
were averaged.
The subthreshold social-defeat and social-interaction test
The subthreshold social-defeat paradigm involved placing the test C57BL/6J mouse into the home cage of a larger retired
breeder mouse (CD1) for 2 min during which time the experimental mouse was physically attacked by the CD1 mouse. After
two bouts of defeat the mouse was returned to its home cage. Mice underwent the social-interaction test 24 h after the defeat
episodes.
The social interaction test (Golden et al., 2011), measured the time spent in the interaction zone, corner zones and locomotor ac-
tivity during the first (CD1 target absent in interaction zone) and second (CD1 target present in interaction zone) trials in an open-field
arena. Mouse movements were automatically monitored and recorded (Smart 3.0, Panlab, S.L.U, Spain) for 2.5 min per each test
session. Behavioral phenotype was based on the social interaction ratio, which was calculated as as a ratio of the time spent in
the interaction and corner zone with target present divided by the time spent in the interaction and corner zonewith the target absent.
All mice with an interaction ratio above 1 and corner ratio below 1 were classified as normal, and all mice with an interaction ratio
below 1 and corner ratio above 1 were classified as being having depression-like behavior.
cFos immunofluorescence
Quantification of cFos expression was performed by counting neurons with mean fluorescence intensity at least 3 times above the
background fluorescence intensity (mean fluorescence intensity of an area without visible neurons). For a quantitative comparison,
we denoted the difference in the numbers of cFos-positive cells in a given brain area of pIONT versus sham mice as follows: *20-50
neurons difference; **50-200 neurons difference; *** > 200 neurons differenceCell Reports 37, 109936, November 2, 2021 e4
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All data are expressed as themean ± s.e.m. Paired-samples t test was used to compare themeans of two groups when the data were
normally distributed. Multiple groups were compared using One-way ANOVA with Bonferroni correction. Pharmacological effects on
the behavioral test were analyzed using repeated-measures ANOVA with Bonferroni correction. An unpaired t test was used to
compare the behavior and electrophysiological results between the pIONT and sham groups. For data that failed the normality
test, the paired sample Wilcoxon signed rank test or Mann-Whitney tests were used. Significance levels were indicated as *p <
0.05, **p < 0.01 and ***p < 0.001. GraphPad Prism 8 (GraphPadSoftware Inc., SanDiego, CA, USA), OriginPro 9.1 software (OriginLab
Corporation, USA) and illustrator (Adobe Systems Incorporated, USA) were used for the statistical analyses and graphing.e5 Cell Reports 37, 109936, November 2, 2021
